arrow
C

Christopher J. Sweeney

south australian immunogenomics cancer institute
H指数:86
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survival

增加癌症干性驱动前列腺癌进展、可塑性、治疗抵抗和患者不良生存

2026-10-270
OAAI
Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)

在标准一线治疗基础上加用恩扎卢胺与标准非甾体抗雄激素药物用于转移性激素敏感前列腺癌患者的成本效益分析:ENZAMET III期国际随机试验(ANZUP 1304)的试验内、次要终点分析

2026-10-050
OAAI
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial

胰岛素样生长因子轴与转移性激素敏感型前列腺癌的生存:来自ENZAMET III期试验的事后分析

2026-09-300
OAAI
Downregulation of ANPEP Is Associated with Aggressive Prostate Cancer and Poor Disease-specific Outcomes

ANPEP的下调与侵袭性前列腺癌及不良疾病特异性预后相关

2025-12-260
OAAI
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024

未来晚期前列腺癌临床研究的路线图:2024年晚期前列腺癌共识会议(APCCC)的研究结果

2025-11-210
PRE
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性

Cell
IF42.5
2025-08-260
OAAI
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial

局部高危前列腺癌的转录组学分析改善了预后判断,并确定了在NRG肿瘤学/RTOG 0521 III期试验中,将多西他赛添加到根治性放疗联合雄激素抑制治疗中获益。

2025-07-170
OAAI
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

循环肿瘤DNA监测和接受阿特珠单抗治疗的转移性实体瘤患者的血液肿瘤突变负荷

2025-05-280
OAAI
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)

循环脂质面板PCPro与转移性激素敏感前列腺癌临床结局的关联:ENZAMET III期随机试验(ANZUP 1304)的事后分析

2025-05-200
PRE
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

前列腺癌生命质量的遗传驱动因素:对E3805 CHAARTED试验中遗传多态性和患者报告结局的评估

2025-04-160
PRE
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468–75

回复Felix Melchior、Andreas Pircher和Isabel Heidegger致编辑的信:关于Johann S. de Bono、Meng He、Chen Shi等人。第3阶段IPATential150试验中接受Ipatasertib和Abiraterone治疗患者的最终总生存期及与临床结局相关的分子数据。欧洲泌尿外科杂志。2025;87:468–75。

2025-04-100
PRE
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

寡转移去势敏感性前列腺癌转移导向治疗联合或不联合雄激素阻断治疗的多机构分析

2024-12-010
OA